Belay Diagnostics Wins Palantir Buildcamp for Second Straight Year
Belay Diagnostics has won Palantir's Foundry for Builders Buildcamp competition for the second consecutive year, this time with a prototype for reviewing complex central nervous system cancer cases. The four-person team built the application during a two-day event in September.
- Belay Diagnostics won Palantir's Buildcamp for a second consecutive year.
- Its four-person team built a molecular case review prototype during a two-day competition.
- The application combines patient histories and CSF liquid biopsy results on an interactive timeline.
- Belay's 2025 winning project focused on automating insurance appeals.
- The company recently achieved SOC 2 attestation after an independent examination of its controls.
Prototype brings clinical and molecular data together
Belay's molecular case review prototype is designed to combine comprehensive patient medical histories with results from the company's cerebrospinal fluid liquid biopsy tests on a single interactive timeline.
According to Belay Diagnostics, the application is intended to help neuro-oncologists and other specialists review complex cases collaboratively. It also supports evaluation of clinical and molecular findings, bringing information into one view for clinical discussions.
The invitation-only competition took place at Palantir's New York City office. Participating organizations were challenged to use Palantir's software to develop working solutions for real business problems.
Second win builds on insurance appeals application
Belay's latest victory follows its 2025 Buildcamp win. That project produced an application designed to help automate insurance appeals by comparing payer policies with individual patient medical histories.
Both applications were developed using Belay's proprietary technology platform, which is built on Palantir Foundry. Outside the competition, Belay says it uses the platform to integrate data across clinical, laboratory, and business operations, add AI to its processes, and create custom applications intended to streamline workflows.
The company said its integrated infrastructure supports its cerebrospinal fluid liquid biopsy testing. Those tests provide molecular insights intended to help inform the diagnosis and management of primary and metastatic central nervous system cancers without requiring tissue.
Platform supports Belay's diagnostic operations
Belay Diagnostics is a Chicago-based laboratory serving patients and clinicians. Using technology licensed from Johns Hopkins University and backed by more than 10 years of scientific research, the company has developed and validated three proprietary cerebrospinal fluid liquid biopsy tests: Belay Summit™ 2.0, Belay Ascent™, and Belay Vantage™.
Belay says its tests provide clinicians with comprehensive molecular insights from a standard lumbar puncture, with a turnaround time of 6-8 calendar days and no tissue required.
The Buildcamp win comes after Belay achieved SOC 2 attestation following an independent examination of its controls. The company said the attestation reflects its investment in protecting sensitive information and building infrastructure to support growth.
“Winning two years in a row speaks to the ingenuity of our team and to their ability to leverage the power of the Palantir platform to deliver critical capabilities to the patients and physicians we serve,” Brian Coe, co-founder and CEO of Belay Diagnostics, said in the company's announcement. Coe added that Belay plans to continue developing tools for clinical trial capabilities and revenue cycle management, with the latter already in use at the company.
